Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
China
The first affiliated hospital of Zhengzhou University, Zhengzhou, Henan West China Hospital of Sichuan University, Chengdu, Sichuan Cancer hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang Beijing Cancer Hospital, Beijing The Fifth Medical Center of PLA General Hospital, Beijing